Torpedo aims to benefit the lives of thousands of cancer patients worldwide by providing superior oncology therapies in the form of next-generation radiopharmaceuticals.

The company is accelerating development of its promising Tb-based radiopharmaceuticals through strategic partnerships with academic institutions and industrial partners. Torpedo also continuously scout for novel technologies to expand their pipeline.

Radioligand therapy

Radioligand
therapy

device for radioligand therapy
  1. 1 Radioactive element
  2. 2 Linker
  3. 3 Cancer-targeting molecule
  4. 4 Cancer cell
  5. 5 Cancer-specific target protein
  6. 6 Specific binding of radiopharmaceutical to cancer target

Radioligand therapy is poised to become one of the most effective treatment modalities in oncology through targeted tumor control.

Two circles, one red and one blue, overlapping each other.

By bridging therapy and diagnostics, Torpedo's radiopharmaceuticals not only provide a best-in-class cancer treatment but also identify cancerous lesions with exceptional accuracy, hence paving the way for an integrated and patient-centric approach.

Seamlessly integrated with advanced imaging modalities, Torpedo's platform enables real-time visualization of treatment responses, allowing for adaptive therapy approaches and informed decision-making.

Backed by rigorous experimental testing, Torpedo's targeted radiopharmaceuticals exhibit versatile applications across various cancer types, with an initial focus on prostate cancer and Gatroenteropancreatic neuroendocrine tumors.

Lead candidate

The Company develops "torpedo molecules" capable of navigating the body in a highly targeted manner, deploying molecular “nuclear bombs" in specifically targeted cancer cells and hence providing a more effective cancer treatment with minimal collateral damage to healthy tissue.

A visual representation of the periodic table element Terbium-161 with symbol and atomic number.

The radionuclide Terbium-161 has several key advantages compared to the current "gold standard" Lutetium-177 (177Lu):

Terbium-161 - A Game-Changer in Cancer Treatment:

  • Terbium-161 delivers a significant advancement in cancer therapy, providing a powerful punch with its emission of Auger electrons. This innovative radionuclide offers a remarkable 3.4 times higher radiation dose to tumors compared to the current gold standard, Lutetium-177, while maintaining a similar safety profile.
  • Terbium-161 combines the power of both beta minus particles and Auger electrons, maximizing the delivery of radiation dose specifically to cancer cells.

The radionuclide Terbium-161 has several key advantages compared to the current "gold standard" Lutetium-177 (177Lu):

  • Surpassing the Standard: Terbium-161 has the potential to revolutionize cancer treatment by by outperforming Lutetium-177 with its superior potency.
  • Precise Strike, Minimal Side Effects: Unlike Actinium-225 (known for severe side effects), Terbium-161's Auger electrons offer a offer an extremely targeted attack (nm-μm range), minimizing off-site toxicity and damage to healthy tissue. This translates to a better therapeutic window and a safer treatment for patients.